Table 1.
Baseline characteristics of enrolled patients.
| Characteristic | Value |
|---|---|
| Patients enrolled, n | 54 |
| Male gender, n (%) | 33 (61.11%) |
| Age, years, mean ± SD | 43.02 ± 8.40 |
| Course of hepatitis B, years, median (interquartile range) | 15.00 (5.50, 21.25) |
| Treatment-naïve, n (%) | 30 (55.56%) |
| NAs-experienced, n (%) | 24 (44.44%) |
| ETV-experienced, n (%) | 11 (20.37%) |
| TAF-experienced, n (%) | 12 (22.22%) |
| TMF-experienced, n (%) | 1 (1.85%) |
| HBV DNA undetectable (<50 IU/mL), n (%) | 25 (46.30%) |
| HBV DNA detectable (>50 IU/mL), n (%) | 29 (53.70%) |
| HBsAg level, IU/ml, median (interquartile range) | 1,668 (446.2, 4,842) |
| HBeAg positive, n (%) | 9 (16.67%) |
| Thickness of spleen, cm, mean ± SD | 3.83 ± 0.67 |
| Length of spleen, cm, mean ± SD | 10.48 ± 1.63 |
| Splenomegaly, n (%) | 31 (57.41%) |
| Diameter of portal vein, cm, mean ± SD | 1.20 ± 0.15 |
| Diameter of portal vein ≥1.3 cm, n (%) | 22 (40.74%) |
| LSM, kPa, median (interquartile range) | 7.40 (5.75, 10.90) |
| ALT, IU/ml, median (interquartile range) | 26.00 (20.00, 36.00) |
| AST, IU/ml, median (interquartile range) | 24.50 (21.00, 32.00) |
| Albumin, g/L, mean ± SD | 44.85 ± 5.07 |
| WBC, ×109/L, mean ± SD | 5.41 ± 1.35 |
| Neutrophils, ×109/L, mean ± SD | 3.11 ± 1.08 |
| Platelets, ×109/L, mean ± SD | 176.3 ± 54.15 |
| HGB, g/L, mean ± SD | 144.8 ± 20.16 |
SD, standard deviation; NAs, nucleos(t)ide analogs; ETV, entecavir; TAF, tenofovir alafenamide; TMF, tenofovir amibufenamide; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B e antigen; LSM, liver stiffness measurement; ALT, alanine aminotransferase; AST, aspartate aminotransferase; WBC, white blood cells; HGB, hemoglobin.